Facing the Enigma of Immunomodulatory Effects of Intravenous Immunoglobulin
- 1 January 2005
- journal article
- review article
- Published by Springer Nature in Clinical Reviews in Allergy & Immunology
- Vol. 29 (3) , 185-200
- https://doi.org/10.1385/criai:29:3:185
Abstract
Intravenous immunoglobulin (IVIg) is a safe remedy for a number of conditions; it is produced from human plasma of thousands of healthy donors. The therapeutic effect of IVIg lies within its content. IVIg contains natural antibodies, which are more polyreactive than immune antibodies, including immunoglobulin G antibodies against endogenous and exogenous antibodies, immunomodulating peptides, and varies cytokines. Beneficial effects of IVIg have been established in immunodeficiencies, as well as in some autoimmune diseases. Also, numerous therapeutic effects of IVIg have been reported over the years in varies autoimmune diseases, recurrent pregnancy loss, and cancer. Many proposed immunoregulatory mechanisms of action of IVIg have been suggested. Some of them have been proven, others are still an enigma, at least in part. Some of these mechanisms entail (a) Fc-receptor blockade; (b) neutralization of pathogenic autoantibodies via idiotypic and anti-idiotypic antibodies; (c) effects on the Fas apoptotic pathway via agonistic and antagonistic anti-Fas autoantibodies; (d) regulation of complement components; (e) modulation of cytokine secretion; (f) hindrance of natural-killer cell activity; (g) inhibition of matrix metalloproteinase-9; (h) suppression of NFkB activation and IkB degradation; (i) G1 cell cycle arrest; (j) prevention of tumor growth; (k) decrease in leukocyte recruitment; (l) attenuation of T-cell stimulation; (m) effects on antibody kinetics; and (n) effects on dendritic cells. The variant mechanisms of IVIg are believed to cooperate in a synergistic way, which all together point to IVIg as a therapeutic preparation with anti-inflammatory, antiself-reactivity, antimetastatic, and embryo-protective effects. This article reviews several main mechanisms of IVIg in order to shed some light on the set of therapeutic effects of IVIg, which are not yet fully understood.Keywords
This publication has 66 references indexed in Scilit:
- IVIg therapy in autoimmunity and related disorders: our experience with a large cohort of patientsAutoimmunity, 2005
- A comparative study of the in vitro immunomodulatory activity of human intact immunoglobulin (7S IVIG), F(ab′)2 fragments (5S IVIG) and Fc fragments. Evidence for post‐transcriptional IL‐2 modulationImmunology, 1997
- Elevated Peripheral Blood Natural Killer Cells Are Effectively Downregulated by Immunoglobulin G Infusion in Women With Recurrent Spontaneous AbortionsAmerican Journal of Reproductive Immunology, 1996
- Absence of Anti-idiotypic Antibodies in IVIG Preparations to Autoantibodies of Rare Autoimmune DiseasesClinical Immunology and Immunopathology, 1995
- Effects of Intravenous Immunoglobulins (IVIG) on Peripheral Blood B, NK, and T Cell Subpopulations in Women with Recurrent Spontaneous Abortions: Specific Effects on LFA-1 and CD56 MoleculesClinical Immunology and Immunopathology, 1994
- Kawasaki disease differs from anaphylactoid purpura and measles with regard to tumour necrosis factor-α and interleukin 6 in serumEuropean Journal of Pediatrics, 1992
- Autoantibodies to cytokines - friends or foes?Immunology Today, 1990
- Peripheral blood monocyte/macrophages and serum tumor necrosis factor in Kawasaki diseaseClinical Immunology and Immunopathology, 1988
- Treatment of Refractory Immune Thrombocytopenic Purpura with an Anti-Fcγ-Receptor AntibodyNew England Journal of Medicine, 1986
- Reversible and irreversible loss of Fc receptor function of human monocytes as a consequence of interaction with immunoglobulin G.Journal of Clinical Investigation, 1980